Tanvir Ahmad, MD
Internal Medicine · Plano, TXNPI 1649280777
Payments from drug & device makers
Across 188 payments — averaging $18,747 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3.4M
- AstraZeneca$99K
- Sanofi US Services Inc.$27K
- Pfizer$11K
- Johnson & Johnson$158
- Lilly USA, LLC$140
- plus $1K from 26 others
Across 8 payments — averaging $7473.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$60K
What the payments were for
- Travel & lodging$4,45962%
- Food & beverage$2,69638%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 78 | $3,384,801 |
| AstraZeneca | 6 | $99,265 |
| Sanofi US Services Inc. | 1 | $27,486 |
| Pfizer | 8 | $11,139 |
| Johnson & Johnson | 10 | $158 |
| Lilly USA, LLC | 11 | $140 |
| Novartis | 7 | $123 |
| Abbott | 6 | $117 |
| Bayer | 5 | $103 |
| Amgen(2 entities) | 5 | $102 |
| GSK | 6 | $98 |
| Dexcom, Inc. | 5 | $94 |
| Medtronic | 4 | $92 |
| Novo Nordisk | 4 | $70 |
| Merck | 4 | $60 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $55 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Gilead | 2 | $43 |
| Boston Scientific | 2 | $38 |
| Exact Sciences | 2 | $37 |
| AbbVie | 2 | $36 |
| Boehringer Ingelheim | 2 | $35 |
| Ironwood Pharmaceuticals, Inc | 2 | $34 |
| Mylan Specialty L.p. | 2 | $34 |
| Corcept Therapeutics | 1 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Edwards Lifesciences | 1 | $25 |
| Vapotherm Inc | 1 | $21 |
| Philips North America LLC | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $16 |
| Analog Devices Inc. | 1 | $11 |
How this compares
$3,524,383 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $54,125 |
| OzempicSemaglutide | 43 | $42,631 |
| JardianceEmpagliflozin | 24 | $33,108 |
| FarxigaDapagliflozin Propanediol | 24 | $31,871 |
| JanuviaSitagliptin Phosphate | 15 | $21,232 |
| LinzessLinaclotide | 17 | $18,855 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $17,691 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $9,906 |
| MounjaroTirzepatide | 11 | $9,457 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $4,812 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 70 | $2,527 |
| Fluticasone Propionate | 118 | $2,421 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,204 |
| Nebivolol Hcl | 16 | $1,193 |
| Omeprazole | 65 | $1,177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $11,139 | $54,12557 claims |
| Novo NordiskOzempic | $70 | $42,63143 claims |
| AstraZenecaFarxiga, Symbicort | $99,265 | $34,07435 claims |
| Boehringer IngelheimJardiance | $35 | $33,10824 claims |
| MerckJanuvia | $60 | $21,23215 claims |
| AbbVieLinzess | $36 | $18,85517 claims |
| GSKTrelegy Ellipta | $98 | $17,69113 claims |
| Lilly USA, LLCMounjaro | $140 | $9,45711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Plano
- Saumil MehtaPlano$5.4M
- Sophia RahmanPlano$3.3M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.